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Gadolinium-based contrast agents (GBCAs) have been widely used in clinical MR imaging since the late 
1980ies. Overall, they were considered safe, apart from the well-known risk of nephrogenic systemic 
fibrosis, which could be counteracted by limitation of their use in patients with renal insufficiency.  
Now however, there have been a number of publications describing the dose-dependent deposition 
of Gadolinium in the brain, manifesting as high signal intensities on non-enhanced T1-weighted images 
particularly in the dentate nucleus and globus pallidus, but also in the thalamus and the pons.1-3   
 
Gadolinium is a rare-earth metal. GBCAs encompass two structurally distinct groups: linear and 
macrocyclic. Some studies suggest that the deposition occurs with linear rather than with macrocyclic 
compounds, and it is thought that linear agents are less stable, leading to dissociation of the contrast 
agent into free gadolinium. 3 
It appears that Gadolinium deposition is independent of age, sex, renal function and interval between 
applications, but happens also with intact blood brain barrier and correlates strongly with the dose 
applied.  
 
Pathological evidence comes from several studies showing Gadolinium deposition in the brain.1,2 
Gadolinium was prominently clustered within the endothelial wall, but had also crossed the blood 
brain barrier and accumulated in the neuronal tissue interstitium. There were, however, no apparent 
histologic changes between contrast and control groups in hematoxylin-eosin–stained tissues samples 
with visual light microscopy.   
 
The gravity of this issue is indicated by the fact that both the Food and Drug Administration (FDA) and 
the European Medicines agency are currently investigating the risk of GBCAs. The communications 
issued by the FDA and the National Institutes of Health (NIH) involve careful consideration of the 
indication of GBCAs, and preferential use of macrocyclic agents.4 
 
This observation is potentially significant for movement disorder neurologists and practitioners for the 
following reasons: Firstly, T1-weighted hyperintensities within the dentate nucleus and the globus 
pallidus would typically evoke a differential diagnosis of manganese, calcium or copper deposition due 
to manganese transporter mutations or hemodialysis, Fahr´s syndrome or Wilson´s disease. 
Gadolinium deposition has now to be added to this list, particularly in patients who also have a past 
history of multiple contrast-enhanced MRI scans. If such patients newly develop a movement disorder, 
the MRI appearance can be a red herring.  
Secondly, so far it is unknown that the Gadolinium deposition has a clinical correlate or leads to adverse 
effects. To date, there are no reports indicating that GBCA exposure might have caused movement 
disorders. However, such symptoms might have been unrecognised or attributed to the disease which 
lead to MR investigations with multiple doses of GBCAs in the first place, e.g. multiple sclerosis. 
There is one study evaluating the incidence of parkinsonism in patients who underwent MR imaging 
with and without GBCAs.5 The authors did not find a significant difference, but there are some 
limitations to this study such as the fact that patients were not systematically assessed, that the 
majority of patients had a single GBCA administration only, that they type of GBCA was not specified 
and that actual Gadolinium deposition was not ascertained.  
Other symptoms associated with lesions of the globus pallidus or the dentate nucleus, such as 
dystonia, abulia or cerebellar signs have not been investigated as yet.  
In contrast, a gadolinium toxicity support group published a survey, in which half of the participants 
reported balance problems, and all participants complained about chronic, mostly neuropathic, pain. 
Although no scientific conclusion can be drawn from this, it underlines the necessity to systematically 
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